Payment overview · 2025
General Payments
$623.58
31 reported records · 13 companies
Healthcare provider profile · identity verified
John Upegui, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HOULTON, ME · NPI 1811272990
Verified facts
What the public records show
CMS Open Payments records show John Upegui, P.A. received $623.58 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.05 | 16.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.32 | 12.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.00 | 10.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.31 | 10.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.42 | 9.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.06 | 9.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.97 | 5.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.98 | 4.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.81 | 4.5% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $25.45 | 4.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.84 | 3.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $22.71 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.66 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.58 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.29 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.42 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.06 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.41 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.97 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
275 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 101 |
| Lisinopril | Lisinopril | 319 | 97 |
| Furosemide | Furosemide | 288 | 102 |
| Gabapentin | Gabapentin | 284 | 88 |
| Eliquis | Apixaban | 275 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 87 |
| Losartan Potassium | Losartan Potassium | 248 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 39 |
| Potassium Chloride | Potassium Chloride | 224 | 59 |
| Metformin Hcl | Metformin Hcl | 204 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 60 |
| Omeprazole | Omeprazole | 193 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 49 |
| Prednisone | Prednisone | 162 | 88 |
| Sertraline Hcl | Sertraline Hcl | 155 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 56 |
| Pregabalin | Pregabalin | 145 | 37 |
| Alprazolam | Alprazolam | 143 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 53 |
| Tramadol Hcl | Tramadol Hcl | 128 | 32 |
| Allopurinol | Allopurinol | 120 | 37 |
| Meloxicam | Meloxicam | 117 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 38 |
| Spironolactone | Spironolactone | 107 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 34 |
| Clonazepam | Clonazepam | 96 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 86 | 13 |
| Montelukast Sodium | Montelukast Sodium | 83 | 27 |
| Glimepiride | Glimepiride | 79 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 57 |
| Ozempic | Semaglutide | 76 | 18 |
| Simvastatin | Simvastatin | 73 | 22 |
| Bumetanide | Bumetanide | 69 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Jardiance | Empagliflozin | 67 | 22 |
| Buprenorphine | Buprenorphine | 63 | suppressed |
| Trulicity | Dulaglutide | 62 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 15 |
| Famotidine | Famotidine | 60 | 17 |
| Sucralfate | Sucralfate | 60 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 16 |
| Carvedilol | Carvedilol | 58 | 19 |
| Trazodone Hcl | Trazodone Hcl | 58 | 22 |
| Ezetimibe | Ezetimibe | 57 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 16 |
| Januvia | Sitagliptin Phosphate | 56 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 23 |
| Glipizide Er | Glipizide | 52 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 13 |
| Fluconazole | Fluconazole | 47 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Nitroglycerin | Nitroglycerin | 44 | 23 |
| Nystatin | Nystatin | 44 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Risperidone | Risperidone | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Atenolol | Atenolol | 42 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | 12 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 25 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 32 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 14 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Glipizide | Glipizide | 32 | 11 |
| Metolazone | Metolazone | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 12 |
| Azithromycin | Azithromycin | 31 | 24 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 14 |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Diazepam | Diazepam | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Xifaxan | Rifaximin | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.58 · 31 records | Novo Nordisk Inc | BREZTRI, Cologuard Collection Kit, JARDIANCE, Kerendia, MONOFERRIC, NURTEC ODT, NUZYRA, Ozempic, PAXLOVID, REXULTI, REZDIFFRA, Rybelsus, SYNTHROID, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error